- Platform
- Roche Ventana Benchmark Ultra
- Clone/manufacturer
- EP356 (760-5086 - Roche Ventana)
- Antibody dilution
- Predilute
- Antibody incubation time/temp
- 16 mins at 36°C
- Antigen retrieval buffer time/temp
- Ventana CC1 32 mins at 100°C
- Amplification
- Not applicable
- Detection kit
- 760-700 Ventana OptiView
- Program (mark)
- General 2019 (5/5)
NKX3.1 is a prostate‑specific, androgen‑regulated nuclear transcription factor essential for normal prostatic epithelial and ductal development. In IHC it shows strong nuclear staining and serves as a highly sensitive and specific marker for identifying tumours of prostatic origin, including metastatic prostate adenocarcinoma. Loss or reduction of NKX3.1 expression is common in prostate carcinoma and high‑grade PIN due to allelic loss, promoter methylation, or post‑transcriptional silencing. Because of its high specificity compared to other prostate markers, NKX3.1 is valuable in confirming prostatic lineage in metastatic lesions of uncertain origin (1).
Recommended Controls
Criteria for acceptable staining is a nuclear staining pattern. The recommended positive control is to include a prostate cancer (high expressor). Testes will show a weak to moderate staining reaction in the spermatogonia (low expressor) and tonsil or appendix which will be negative.
Expected staining pattern

Prostate cancer

Testes
Disclaimer
These methods are intended as a guide only. Laboratories that wish to implement these methods should perform internal validation/verification prior to use. The RCPAQAP does not make any claim or warranty for the accuracy or performance of these methods.
References
Thakur S, Enwere E. NKX3.1. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/stainsnkx3.html.
Images of prostate cancer and normal testes_QAP survey results